Drug Discovery Today Therapeutic Strategies Template
Write in a clean editor, then format for Drug Discovery Today Therapeutic Strategies in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
About the Drug Discovery Today Therapeutic Strategies format
Drug Discovery Today Therapeutic Strategies is a peer-reviewed journal published by Elsevier, covering Receptor Mechanisms and Signaling, Neuroscience and Neuropharmacology Research, Immunotherapy and Immune Responses.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Drug Discovery Today Therapeutic Strategies 12 (2023) 45–58.
Formats any DOI in Drug Discovery Today Therapeutic Strategies style. No sign-up. |
| Publishes research in | Receptor Mechanisms and Signaling Neuroscience and Neuropharmacology Research Immunotherapy and Immune Responses Computational Drug Discovery Methods Monoclonal and Polyclonal Antibodies Research |
| ISSN | 1740-6773 |
| h-index | 32 |
| i10-index | 126 |
| Total citations | 4,508 |
| Top institutions publishing here | Inserm |
| Journal website | www.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Papers published in Drug Discovery Today Therapeutic Strategies per year
Citation impact of Drug Discovery Today Therapeutic Strategies by publication year
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Most-cited papers in Drug Discovery Today Therapeutic Strategies
The natriuretic peptide system exerts beneficial cardiorenal effects in chronic heart failure, whereas activation of the renin–angiotensin–aldosterone system exerts opposing and deleterious effects. LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, targets both neurohormonal systems by inhibiting neprilysin, which prevents natriuretic peptide degradation, while concomitantly blocking the angiotensin (AT1) receptor. In clinical studies of patients with…